Cinda Biotech (01801) rose more than 6%. As of press release, it rose 6.22% to HK$38.4, with a turnover of HK$299 million.
The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 6%. As of press release, it had risen 6.22% to HK$38.4, with a turnover of HK$299 million.
According to the news, Global Data released a report saying that due to a surge in demand for weight loss products, pharmaceutical companies are preparing to launch about 13 new weight loss treatments in the US within the next five years. The agency said it is expected that the number of diet pills on the market will increase dramatically, reaching a peak of four models per year in 2027 and 2028. In contrast, only three products were launched between 2019 and 2023.
According to CITIC Construction Investment, CITIC Biotech officially submitted a marketing application for Maxidopeptide to the CDE on February 7, 2024. The indications are patients who are overweight with related diseases or obesity. The application dosage is 2, 4, and 6 mg. From the beginning of phase III clinical trials in late 2022, the first patient enrollment in January 2023, and the NDA in early 2024, the high clinical trial efficiency demonstrated the company's first-class execution. As the first domestically produced dual-target GLP-1 drug, we believe that Mastopeptide is expected to be approved for marketing in the first half of 2025, bringing new drug options for overweight or obese patients in China.